Triple Therapy in COPD: Can We Welcome the Reduction in Cardiovascular Risk and Mortality?

Frontiers in Medicine

article

Paolo Solidoro¹  Carlo Albera¹  Fulvia Ribolla¹  Michela Bellocchia¹  Luisa Brussino²  Filippo Patrucco⁴ 

[1] Division of University Respiratory Medicine, Cardiovascular and Thoracic Department;Department of Medical Sciences, University of Turin;Allergy and Clinical Immunology Unit, AO Ordine Mauriziano Hospital;Division of Respiratory Diseases, Medical and Specialistic Department;Translational Medicine Department, University of Piemonte Orientale

关键词: chronic obstructive pulmonary disease (COPD);    triple inhaled therapy;    ICS;    LAMA;    LABA;    CV mortality;   

DOI  :  10.3389/fmed.2022.816843

学科分类：社会科学、人文和艺术（综合）

来源: Frontiers

【 摘 要 】

Chronic obstructive pulmonary disease (COPD) is a complex disease which consists in the reduction of the airflow and leads to the disruption of the pulmonary tissue due to a chronic inflammation. The progression of the disease is characterized by an exacerbation of the symptoms and the presence of life-threatening systemic complications, such as stroke and ischemic heart disease, with a progressive decline in lung function which can deeply impact the quality of life. Mortality represents the most important COPD outcome, with an increased risk in patients with cardiovascular comorbidities. The efficacy and safety of triple inhaled therapy were demonstrated by numerous controlled trials. Above all, many robust data are now available on the effectiveness of the triple therapy to reduce mortality in COPD patients.

【 授权许可】

CC BY